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A variety of chemokines and inflammatory 
molecules are concomitantly produced at sites 
of inflammation and tissue damage and are 
responsible for leukocyte trafficking and homing. 
Although we understand reasonably well the 
effects of these molecules individually, much 
less is known about the consequences of the 
combined activity of chemokines with other 
chemokines or inflammatory molecules.
Chemokines control integrin function and 
cell locomotion (Murphy, 2002) by binding to 
seven transmembrane domain receptors cou-
pled to heterotrimeric GTP-binding proteins 
(GPCRs [G-protein–coupled receptors]), which 
are differentially expressed in a wide range of 
cell types. The resulting combinatorial diver-
sity in responsiveness to chemokines guarantees 
the proper tissue distribution of distinct leuko-
cyte subsets under normal and pathological 
conditions. The chemokine CXCL12 binds to 
the chemokine receptor CXCR4 and plays an 
essential and unique role in homeostatic reg-
ulation of leukocyte traffic, hematopoiesis, 
organogenesis, cell differentiation and tissue 
regeneration (Murphy, 2002).
Many molecules involved in triggering 
inflammation have chemoattractant activities. 
These include pathogen-associated molecular 
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After tissue damage, inflammatory cells infiltrate the tissue and release proinflammatory 
cytokines. HMGB1 (high mobility group box 1), a nuclear protein released by necrotic and 
severely stressed cells, promotes cytokine release via its interaction with the TLR4 (Toll-like 
receptor 4) receptor and cell migration via an unknown mechanism. We show that HMGB1-
induced recruitment of inflammatory cells depends on CXCL12. HMGB1 and CXCL12 form a 
heterocomplex, which we characterized by nuclear magnetic resonance and surface plas-
mon resonance, that acts exclusively through CXCR4 and not through other HMGB1 recep-
tors. Fluorescence resonance energy transfer data show that the HMGB1–CXCL12 
heterocomplex promotes different conformational rearrangements of CXCR4 from that of 
CXCL12 alone. Mononuclear cell recruitment in vivo into air pouches and injured muscles 
depends on the heterocomplex and is inhibited by AMD3100 and glycyrrhizin. Thus, inflam-
matory cell recruitment and activation both depend on HMGB1 via different mechanisms.
© 2012 Schiraldi et al. This article is distributed under the terms of an Attribution– 
Noncommercial–Share Alike–No Mirror Sites license for the first six months 
after the publication date (see http://www.rupress.org/terms). After six months it is 
available under a Creative Commons License (Attribution–Noncommercial–Share 
Alike 3.0 Unported license, as described at http://creativecommons.org/licenses/
by-nc-sa/3.0/).
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HMGB1, as determined by fluorescence resonance energy 
transfer (FRET).
We then investigated how HMGB1 and CXCL12 
cooperate in promoting cell migration in vitro and in vivo. 
We show evidence that in the initial phase of tissue injury, 
the recruitment of mononuclear cells is mediated by the 
CXCL12–HMGB1 complex, which signals via CXCR4, 
whereas both RAGE- and TLR-mediated signaling are 
dispensable. Thus, the recruitment of inflammatory cells to 
damaged tissues appears distinct from the induction of cyto-
kine release from the same cells, which depends on the TLR4 
receptor, although both processes involve HMGB1.
RESULTS
HMGB1-induced migration of fibroblasts is inhibited  
by blocking CXCR4 or CXCL12
HMGB1 is a chemoattractant for a variety of cells; however, 
recent work has demonstrated that the redox state of HMGB1 
affects its properties (Yang et al., 2012). The recombinant 
HMGB1 used throughout this work is fully reduced: it was 
purified and stored in the presence of DTT, and mass spec-
trometry confirmed that its three cysteine residues are in the 
thiol state (Fig. 1 A).
Already in the first description of the chemoattractant ac-
tivity of HMGB1 it was noted that the response of primary 
rat aortic smooth muscle cells to HMGB1 is sensitive to PTX 
pretreatment (Degryse et al., 2001). In mouse NIH/3T3 fi-
broblasts, HMGB1-induced migration was also blocked by 
PTX, as well as by a selective antibody to the chemokine 
receptor CXCR4 and by the specific CXCR4 antagonist, 
AMD3100 (Fig. 1 B). In addition, HMGB1 did not induce 
migration of embryonic fibroblasts lacking CXCR4 (Fig. 1 C). 
A direct interaction of HMGB1 with CXCR4 was excluded 
by pull-down experiments performed on a lysate of mouse 
pre-B 300.19 cells transfected with CXCR4: CXCR4 was 
pulled down with 500 nM of biotinylated CXCL12 but not 
with 500 nM of biotinylated HMGB1 (Fig. 1 D).
To test the possibility that HMGB1-induced cell migration 
involves the interaction of CXCL12 with CXCR4, we tested 
the migration toward HMGB1 in the presence of a neutraliz-
ing anti-CXCL12 antibody. Indeed, the antibody blocked 
HMGB1-induced migration (Fig. 1 E). These experiments 
suggested that CXCL12 is necessary for HMGB1 to induce 
cell migration. They also indicate that CXCL12 is already 
available in the medium in which the cells are cultured or sus-
pended or is made available after the exposure of the cells to 
HMGB1. In fact, both 3T3 cells (Fig. 1 F) and freshly isolated 
human monocytes (Fig. 1 G) released a basal level of CXCL12; 
this level was significantly increased after the exposure of the 
cells to HMGB1, in accordance with the recent observation 
that HMGB1 induces Cxcl12 transcription (Penzo et al., 2010). 
The release of CXCL12 from HMGB1-stimulated cells de-
pends on the presence of RAGE: embryonic fibroblasts from 
C57BL/6 mice lacking RAGE (Rage/) secreted a reduced 
amount of CXCL12 in response to HMGB1 compared with 
cells from WT animals (Fig. 1 H).
patterns, such as LPS and N-formylated peptides (Chen 
and Pan, 2009), and damage-associated molecular patterns, 
which are endogenous molecules that signal cell distress 
and traumatic cell death and include IL-1, S100 pro-
teins, defensins, and HMGB1 (high mobility group box 1; 
Bianchi, 2009).
HMGB1 is a ubiquitously expressed, highly conserved 
nuclear protein that plays important roles in chromatin 
organization and transcriptional regulation (Bianchi, 2009). 
HMGB1 acts as a damage-associated molecular pattern after 
its release, which can occur passively from dead cells (Bianchi, 
2009) or actively by secretion from activated immune cells, 
enterocytes, hepatocytes, and possibly several other types of 
cells under distress (Tsung et al., 2007). Secretion requires the 
translocation of HMGB1 from the nucleus to the cytoplasm 
and does not involve the endoplasmic reticulum and the 
Golgi apparatus (Wang et al., 1999; Bianchi, 2009). Stress 
conditions that induce HMGB1 secretion include hypoxia 
(Andrassy et al., 2008), treatment with specific antitumor 
drugs (Ditsworth et al., 2007), or lethal irradiation (Apetoh et al., 
2007). Recently, it has emerged that the relocation of HMGB1 
from the nucleus to the cytoplasm also controls autophagy 
and in turn autophagic cells can secrete HMGB1 (Livesey et al., 
2009; Skinner, 2010; Tang et al., 2010).
Extracellular HMGB1 induces several responses, includ-
ing the release of proinflammatory cytokines, cell prolifera-
tion, and cell migration (Bianchi, 2009). Several receptors 
have been implicated in HMGB1-mediated functions, in-
cluding RAGE (receptor for advanced glycation end prod-
ucts) and TLR2 (Toll-like receptor 2), TLR4, and TLR9 
(Lotze and Tracey, 2005; Tian et al., 2007). Downstream 
signaling is not completely understood, but involves Src, 
MAPK (mitogen-activated protein kinase), and NF-B acti-
vation (Palumbo et al., 2009; Penzo et al., 2010). Moreover, 
the migration of immature DCs and smooth muscle cells in 
response to HMGB1 is sensitive to Bordetella pertussis toxin 
(PTX), indicating the involvement of GPCRs (Degryse et al., 
2001; Yang et al., 2007), coupled to Gi/0 proteins.
It is currently not known whether all receptors and all 
signaling pathways are required for the different responses to 
HMGB1; recent evidence suggests that TLR4 but not RAGE 
is required for cytokine release (Yang et al., 2010) and that 
RAGE is involved in cell migration (Penzo et al., 2010). Sur-
prisingly, HMGB1-induced cell migration requires activation 
of both the canonical and noncanonical NF-B pathways, 
which lead to the transcription of the Cxcl12 gene (Penzo 
et al., 2010). In addition, HMGB1 protects CXCL12 from 
degradation, suggesting both a functional and physical in-
teraction between the molecules (Campana et al., 2009). 
We show here by nuclear magnetic resonance (NMR) and 
surface plasmon resonance (SPR) analysis that HMGB1 and 
CXCL12 form a complex. Importantly, HMGB1 induces 
changes in residues 3–12 of CXCL12, which are fundamen-
tal for the triggering of CXCR4, the CXCL12 receptor. The 
conformational rearrangements of CXCR4 homodimers dif-
fer when triggered by CXCL12 alone or in complex with 
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HMGB1 enhances CXCL12-induced migration,  
extracellular signal-regulated kinase (ERK) phosphorylation, 
and intracellular Ca2+ mobilization in human monocytes  
and CXCR4-transfected cells
We further investigated in vitro whether HMGB1 and CXCL12 
cooperate in modulating cell migration or whether the migra-
tion observed in the presence of HMGB1 is exclusively induced 
by CXCL12. As shown in Fig. 2 A, 1 nM CXCL12 did not in-
duce migration of human monocytes, whereas optimal migra-
tion was observed at 100 nM. HMGB1 alone did not induce 
migration up to 300 nM (not depicted). In the presence of 
300 nM HMGB1, CXCL12 induced strong monocyte migration 
already at 1 and 10 nM. We determined, by dose finding experi-
ments, that 150 nM is the lowest HMGB1 concentration that 
can enhance migration in the presence of a suboptimal CXCL12 
concentration (10 nM; Fig. 2 B). HMGB1 does not enhance the 
activity of other inflammatory chemokines, such as CXCL8, 
CCL2, and CCL7, and only marginally enhances CCL19- and 
CCL21-induced migration (not depicted).
Chemokines, upon activation of their selective receptors, 
induce intracellular signaling cascades involved in cell activa-
tion and motility, such as ERK phosphorylation and Ca2+ re-
lease from stores. In the presence of a suboptimal CXCL12 
concentration (0.5 nM), we could detect ERK phosphoryla-
tion in human monocytes in the presence of 75 nM HMGB1 
(Fig. 2 C) but not in the presence of CXCL12 or HMGB1 
alone. As a control, phosphorylation of ERK was induced 
by an optimal CXCL12 concentration (10 nM). Similar results 
were obtained when assessing CXCL12-induced intracellular 
Ca2+ mobilization in pre-B 300.19/CXCR4+ cells in the 
presence or absence of HMGB1. A rapid increase of intracel-
lular Ca2+ was observed in cells stimulated with a high con-
centration of CXCL12 (100 nM) but not in cells stimulated 
with a suboptimal CXCL12 concentration (10 nM) or with 
75 nM HMGB1 alone. However, a suboptimal CXCL12 
concentration (10 nM) induced intracellular Ca2+ rise in the 
presence of 75 nM HMGB1, similar to the one observed with 
100 nM CXCL12 (Fig. 2 D).
Glycyrrhizin, the glycoconjugated triterpene produced 
by the licorice plant Glycyrrhiza glabra, inhibits the chemoat-
tractant and mitogenic activities of HMGB1 on 3T3 fibro-
blasts and binds to both HMG-box domains (BoxA and 
BoxB; Mollica et al., 2007). Glycyrrhizin did not affect 
CXCL12-induced migration (Fig. 2 E) but abrogated the 
synergistic effect exerted by HMGB1 (Fig. 2 F).
Figure 1. Migration of mouse fibroblasts in the presence of 
HMGB1 requires CXCR4/CXCL12. (A) Deconvoluted mass spectra of 
recombinant HMGB1 used throughout our work. The mass of 24,747 cor-
responds to the fully reduced state of HMGB1 (amino acids 2–215; the 
first methionine is absent both in mammalian and in bacterially produced 
HMGB1). (B) Migration of murine NIH/3T3 in the presence of 1 nM 
HMGB1 is 100 nM PTX–sensitive, and it is blocked by 2 µg/ml anti-CXCR4 
antibody or by 1 µM of the CXCR4 antagonist AMD3100. Migrated cells 
were counted per high-power field (HPF) and are shown as mean ± SEM 
of three independent experiments (***, P < 0.005 vs. HMGB1 using ANOVA 
plus Dunnett’s test). (C) Migration of Cxcr4+/ and Cxcr4/ embryonic 
fibroblasts (MEFs) in the presence of 1 nM HMGB1 or 10 ng/ml PDGF. 
Migrated cells were counted per high-power field and are shown as mean ±  
SEM of three independent experiments (***, P < 0.001 using ANOVA 
plus Bonferroni posttest). (D) Pull-down of CXCR4 from cell lysates of 
pre-B 300.19–CXCR4+ was performed with 500 nM of biotinylated 
CXCL12 or 500 nM of biotinylated HMGB1 and analyzed by Western blot. 
Nonbiotinylated CXCL12 or HMGB1 was used at 500 nM as control. Den-
sitometric analysis of the bands obtained in three independent experi-
ments (mean ± SEM) is shown. (E) Migration in the presence of HMGB1 is 
blocked by 1 µg/ml anti-CXCL12. Migrated cells were counted per high-
power field and are shown as mean ± SEM of three independent experi-
ments (***, P < 0.005 vs. HMGB1 using ANOVA plus Dunnett’s test).  
(F–H) CXCL12 as detected by ELISA in the supernatant of mouse 3T3 (F), human 
monocytes (G), or Rage/ MEFs (H) stimulated with 4 nM HMGB1 for 2 h. 
Mean ± SEM of three independent experiments is shown (**, P < 0.01).
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HMGB1 enhances CXCL12-induced migration exclusively via 
CXCR4 and in a RAGE- and TLR-independent manner
The synergy of HMGB1 and CXCL12 might require HMGB1 
receptors (RAGE, TLR2, or TLR4), CXCL12 receptors 
(CXCR4), or both. Freshly isolated human monocytes ex-
press CXCR4, TLR2, and TLR4 on their surface, whereas 
RAGE expression can be detected only at the RNA level 
(not depicted). To test which receptors are required, we used 
BM cells from C57BL/6 mice, either WT or lacking RAGE 
(Rage/), the proximal interactor of TLR receptors MyD88 
(MyD88/), or TLR4 (Tlr4/). WT BM cells migrated 
with a typical bell-shaped dose response to CXCL12 alone, 
and HMGB1 shifted the bell-shaped curve to lower CXCL12 
concentrations (Fig. 3 A). BM cells from MyD88/, Rage/, 
and Tlr4/ mice responded to CXCL12 and to the presence 
of HMGB1 similarly to WT BM cells (Fig. 3, B–D). Addi-
tionally, Rage/ BM cells in the presence of the inhibitory 
TLR4 molecule, LPS-Rs (Maroso et al., 2010), did not modify 
the response to CXCL12 in the presence of HMGB1 (Fig. 3 E), 
indicating that neither RAGE nor TLR signaling is involved 
in the synergy between HMGB1 and CXCL12 and suggest-
ing that the effect of HMGB1 on cell migration is mediated 
by CXCR4 alone. In support of this hypothesis, we used 
pre-B 300.19 cells, in which RAGE, TLR2, and TLR4 are 
not present and which do not respond to CXCL12 (not 
depicted). When we stably transfected pre-B 300.19 cells 
with human CXCR4, we observed a 100-fold increase in 
the chemoattractant potency of CXCL12 in the presence of 
300 nM HMGB1 (Fig. 3 F).
HMGB1 forms a heterocomplex with CXCL12
Synergy between HMGB1 and CXCL12 depends on CXCR4, 
but we could not show a direct interaction of HMGB1 with 
CXCR4 (Fig. 1 D). The synergy does not depend on RAGE, 
TLR2, or TLR4, suggesting that HMGB1 and CXCL12 
might form a physical complex that acts on CXCR4. Modu-
lation of chemokine activities has been shown to occur via 
the formation of heterocomplexes in vitro (Paoletti et al., 
2005; von Hundelshausen et al., 2005) and in vivo (Koenen 
et al., 2009).
We confirmed that purified HMGB1 and CXCL12 can 
form a complex upon mixing: two different anti-CXCL12 
antibodies coimmunoprecipitated HMGB1 (not depicted). 
To observe and characterize the interaction between CXCL12 
and HMGB1, we then used NMR chemical shift mapping. 
By comparing 15N-labeled heteronuclear single-quantum 
Figure 2. HMGB1 increases CXCL12-induced activities in human 
monocytes and CXCR4-transfected cells and is sensitive to glycyr-
rhizin. (A) Chemotaxis toward increasing concentrations of CXCL12 ±  
300 nM HMGB1. Migrated cells were counted per five high-power fields (HPF) 
and are shown as mean ± SEM of three independent experiments per-
formed with cells from different donors (*, P < 0.05; **, P < 0.01, ANOVA 
plus Bonferroni posttest). (B) Dose–response curve of HMGB1 in the pres-
ence of 10 nM CXCL12. Migrated cells were counted per five high-power 
fields and are shown as mean ± SEM of three independent experiments. 
(C) Time course of ERK1&2 phosphorylation induced by CXCL12 alone or 
in the presence of HMGB1. The intensity of pERK1&2 bands was analyzed 
by densitometry, normalized with matching GAPDH, and compared with 
the unstimulated control. One representative blot is shown; the bars and 
error bars represent mean ± SEM of four independent experiments with 
cells from different donors. (D) Changes in [Ca2+]i were monitored in cells 
loaded with 50 nM Fura-2-AM and stimulated with CXCL12 and HMGB1. 
One representative set of measurements out of three independent experi-
ments is shown. (E and F) Chemotaxis toward increasing concentrations 
of CXCL12 ± 200 µM glycyrrhizin ± 300 nM HMGB1. In all these experi-
ments, migrated monocytes were counted per five high-power fields. Bars 
and error bars represent mean ± SEM of three different experiments per-
formed with monocytes from different donors (**, P < 0.01, ANOVA plus 
Bonferroni posttest).
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BoxB (which have a very similar structure but are only 20% 
identical at the amino acid level). In the reverse experiments, 
we added CXCL12 to 15N-labeled BoxB: 44 out of 80 BoxB 
residues were affected by CXCL12 binding, confirming 
the interaction and pinpointing it to the concave surface 
formed by the BoxB helices (Fig. 4, D and E). Intriguingly, 
this is the site where glycyrrhizin binds to HMGB1 (Mollica 
et al., 2007).
The addition of HMGB1 to 15N-CXCL12 at a 1:2 ratio 
caused more extensive (57 of 68 residues) and profound changes 
in the NMR spectrum of CXCL12 (Fig. 4, A, B, and F–G) 
than those induced by individual HMG-boxes. Only one set 
of peaks was present, and no signal corresponding to free 
CXCL12 was observed, suggesting a (CXCL12)2(HMGB1) 
stoichiometry. CXCL12 can bind to both HMG-box do-
mains independently but displays different chemical shifts; 
because a single set of peaks was observed, this suggests 
that the heterocomplex is dynamic and the CXCL12 mole-
cules exchange between the free state, BoxA binding, and 
BoxB binding.
Residues 3–12 in the N terminus of CXCL12, which 
are directly involved in CXCR4 recognition and trigger-
ing (Crump et al., 1997), were affected by the binding of 
full-length HMGB1 but not of either BoxA or BoxB alone 
(Fig. 4, A, B, and F–G). HMGB1 also affected the 31–35 
loop, which is spatially close to the N terminus. This sug-
gests that HMGB1 might induce a rearrangement of the 
CXCL12 conformation capable of enhancing the CXCL12- 
induced responses.
SPR experiments show that CXCL12 can bind to 
HMGB1 immobilized on the sensor surface, with signal in-
tensity increasing with increasing concentrations of CXCL12. 
The intensity decreased, instead, in the presence of increasing 
concentrations of glycyrrhizin (Fig. 4 C), indicating that this 
small molecule inhibits the HMGB1–CXCL12 interaction. 
This supports and strengthens our NMR data because glycyr-
rhizin is known to bind HMGB1 (Mollica et al., 2007) in the 
same region where CXCL12 binds according to our map-
ping experiments.
CXCL12 and HMGB1–CXCL12 complexes interact 
differently with CXCR4 homodimers
To test whether CXCL12 and the HMGB1–CXCL12 com-
plex interact similarly or differently with CXCR4, we used 
sensitized FRET. HEK293 cells were transiently cotransfected 
with constant amounts of donor (CXCR4 fused to CFP; 
CXCR4-C) and increasing amounts of acceptor (CXCR4 
fused to YFP; CXCR4-Y), and FRET saturation curves were 
determined. The results indicate that CXCR4 homodi-
merizes in the absence of ligands (FRETmax, 0.708 ± 0.008; 
FRET50, 1.274 ± 0.042); this process is specific, as in HEK293 
cells coexpressing constant amounts of CXCR4-CFP and 
increasing amounts of mGluR1-YFP, a seven-transmembrane 
receptor used as negative control, the FRET signal was 
negligible (FRETmax, 0.144 ± 0.024; FRET50, ND; Fig. 5 A). 
To determine the effect of ligand binding on CXCR4 
coherence (HSQC) spectra before and after addition of the 
partner, it is possible to confirm an interaction even between 
low-affinity binding partners (Varani et al., 2007) and also to 
deduce which residues are affected.
We first recorded the NMR spectra of free 15N-labeled 
CXCL12 and subsequently added either unlabeled HMGB1 
or one of its HMG-box domains, BoxA or BoxB. The NMR 
signal of 38 out of 68 CXCL12 residues shifted upon addi-
tion of an equimolar amount of BoxB, proving that the two 
molecules interact (Fig. 4 A). The majority of the changes in 
CXCL12 involve residues 13–25, 40–45, and the C termi-
nus, whereas the N terminus of CXCL12, in particular the 
flexible first 8 aa required for CXCR4 triggering (Crump 
et al., 1997; Wu et al., 2010), are clearly not affected by 
BoxB. Most CXCL12 residues involved in the interaction 
with BoxB were also affected by the addition of BoxA, but 
the chemical shift changes were slightly different and gener-
ally smaller in magnitude (Fig. 4 A), probably reflecting inter-
actions with residues not conserved between BoxA and 
Figure 3. HMGB1 enhances CXCL12-induced migration via CXCR4 
and is independent from RAGE or TLR signaling. (A–F) Migration in-
duced by CXCL12 ± 300 nM HMGB1 on murine BM cells from C57BL/6 WT 
(A), MyD88/ (B), Rage/ (C), Tlr4/ (D), and Rage/ in the presence 
of 10 µg/ml LPS-Rs (E) or murine pre-B 300.19 cells transfected with  
human CXCR4 (F). Migrated cells were counted in five high-power fields 
(HPF) and are shown as mean ± SEM of four independent experiments 
performed with cells from different mice (**, P < 0.01; ***, P < 0.005, 
ANOVA plus Bonferroni posttest).
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did not change significantly (1.548 ± 0.122 vs. 1.274 ± 0.042 
in untreated controls; P > 0.05), indicating that both CXCR4 
partners are bound apparently with similar affinity, but 
FRETmax increased significantly (0.8636 ± 0.029 vs. 0.708 ± 
0.008 in controls; P < 0.05), indicating a change in confor-
mation of CXCR4 dimers (Fig. 5 C). In contrast, stimula-
tion with HMGB1–CXCL12 did not cause a significant 
modification of FRETmax (0.7462 ± 0.013 vs. 0.708 ± 0.008 
in controls; P > 0.05) but significantly increased FRET50 
(1.612 ± 0.08 vs. 1.274 ± 0.042 in controls; P < 0.05), 
homodimers, HEK293 cells transiently cotransfected with 
CXCR4-C/CXCR4-Y, as above, were stimulated with 
CXCL12 alone or in combination with HMGB1, and sensi-
tized FRET was determined as above (Fig. 5 B). The maxi-
mal FRET signal (FRETmax) depends on FRET efficiency, 
which is affected by the distance and the relative orientation 
between the fluorescent proteins. The apparent affinity be-
tween CXCR4 monomers is defined by FRET50, the num-
ber of CXCR4 complexes at which half-maximal FRET 
signal is observed. In the presence of CXCL12 alone, FRET50 
Figure 4. NMR analysis of CXCL12 interactions with HMGB1, BoxA, and BoxB. (A) Chemical shift perturbation analysis of CXCL12 in complex 
with HMGB1, BoxA, or BoxB, calculated as described in Materials and methods. (B) 15N-HSQC spectra of CXCL12 free (blue) and in complex with HMGB1 
(red); some of the residues showing chemical shift changes upon complex formation are labeled. (C) SPR sensograms of the interaction between HMGB1 
and CXCL12 in the presence of increasing concentrations of glycyrrhizin. HMGB1 was immobilized on the sensor surface according to standard tech-
niques, and 500 nM CXCL12 was then passed over the surface. CXCL12 (blue) shows a typical response curve with the signal increasing while the protein 
is flowed over the surface and decreasing after it stops flowing. In the presence of 500 nM glycyrrhizin (green), the signal intensity decreases and de-
creases further in the presence of 5 µM glycyrrhizin (red), which is indicative of decreased CXCL12 binding. The experiment was reproduced three times 
with the same results. RU, response units. (D and E) Cartoon (D) and surface (E) representation of BoxB: residues with significant chemical shift changes 
upon the addition of CXCL12 are in red. (F and G) Similar representation of CXCL12 residues showing NMR chemical shift changes upon binding of BoxA 
or BoxB are in blue; residues that change only upon the addition of HMGB1 are in green.
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CXCL12 on endothelial cells (not depicted). To measure the 
amount of circulating HMGB1–CXCL12 heterocomplex, 
we set up a hybrid ELISA in which the surface-bound anti-
body captured CXCL12 and the detection antibody recog-
nized HMGB1 (see Materials and methods). Using this hybrid 
ELISA, we confirmed the presence of the HMGB1–CXCL12 
heterocomplex in the muscles 2 h after injury (Fig. 6 B). We also 
assessed the level of cytokines that are involved in inflam-
matory reactions 2 and 6 h after CTX injury (Fig. 6 C). IL-6 
was already released at 2 h, indicating an influx of mono-
cytes. IL-10 and CCL2 were released at a later time (6 h), and 
low concentrations of TNF were detected during the first 
hours after injury. These results suggest that the activity of the 
complex HMGB1–CXCL12 induces the recruitment of mono-
cytes soon after the injury, whereas the release of CCL2, 
a potent monocyte chemoattractant, supports cell influx at 
later times.
To verify that the initial monocyte/macrophage recruit-
ment after muscle injury is mainly caused by the CXCL12/
CXCR4 axis, we recovered and counted monocytes/
macrophages by flow cytometry after CXCR4 blockage 
with its specific antagonist AMD3100 (DiPersio et al., 2009). 
AMD3100 (430 µg per day) or PBS was infused continuously 
(Jujo et al., 2010) over 3 d from an implanted osmotic pump. 
At day 3, mice were treated with CTX, and the injured and 
contralateral TA muscles were collected after 6 h. Although 
AMD3100 induced higher levels of circulating BM cells, as 
expected (DiPersio et al., 2009), the influx of monocytes/
macrophages into the injured TA muscle was significantly 
decreased compared with the PBS-treated mice (Fig. 6 D), 
confirming that the initial cell recruitment is mainly medi-
ated by CXCR4.
To fully characterize the role of HMGB1 in CXCL12-
dependent migration in vivo, we used an anti-HMGB1 
monoclonal antibody known to block HMGB1 activities 
in vitro and in vivo (Sitia et al., 2011) and glycyrrhizin, 
indicating that HMGB1–CXCL12 increases the number of 
CXCR4 dimers formed and does not cause the same rear-
rangement in CXCR4 complexes as CXCL12 alone. This 
observation was confirmed, as we detected a significant 
difference in FRETmax (P < 0.05) between cells activated 
with CXCL12 alone and those stimulated with HMGB1–
CXCL12 (Fig. 5 C).
HMGB1 and CXCL12 cooperate to induce cell migration  
in vivo via CXCR4 and in a RAGE-independent manner
CXCL12 is one of the most abundant chemokines and is 
expressed on the endothelial vessels, ensuring trafficking of 
blood cells expressing CXCR4 in basal (homeostatic) condi-
tions. Based on our in vitro experiments, the HMGB1–
CXCL12 heterocomplex is much more active than CXCL12 
alone. To test the in vivo relevance of the HMGB1–CXCL12 
heterocomplex, air pouches were established in C57BL/6 
mice, and 10 pmol CXCL12 was injected alone or together 
with HMGB1. As shown in Fig. 6 A, the complex induced a 
massive influx of WBCs 6 h after injection and was much 
more potent than CXCL12 alone.
The results reported in the previous sections suggest 
that HMGB1 released as a result of tissue damage promotes 
monocyte recruitment to the injured tissue by using CXCR4 
as a receptor. To test this hypothesis, we studied the initial 
phase of mononuclear cell migration in a model of muscle 
injury induced by cardiotoxin (CTX) injection. A single dose 
of CTX was injected in the tibialis anterior (TA) muscle of 
BALB/c WT mice. CTX injury induced the infiltration of a 
mononuclear cell population positive for CD11b and Ly6C 
already at 3 h after injection (not depicted). The amount of 
transcripts specific for mononuclear cells (CD11b, CD11c, 
Ly6c, CCL2, and CCR2) in the entire TA muscle increased 
as early as 3 h after CTX damage and remained elevated up 
to 48 h later (not depicted). HMGB1 was present in both 
myocytes and inflammatory cells and was also colocalized with 
Figure 5. CXCL12 and the CXCL12–HMGB1 heterocomplex trigger different conformational changes in CXCR4 homodimers. (A and B) FRET 
saturation curves were generated in HEK293T cells transiently cotransfected with a constant amount of CXCR4-CFP (CXCR4-C; 2.0 µg; 300,000 FU) and 
increasing quantities of CXCR4-YFP (CXCR4-Y; 0.25–4.25 µg; 80,000-2,000,000 FU) or mGluR1-Y (0.5–6.0 µg; 110,000-2,100,000 FU) as negative 
control. The curves represent data obtained in eight independent experiments. (B) Effect of CXCL12 (100 nM, 30 min) or CXCL12 + HMGB1 (100 nM and 
300 nM, 30 min) on CXCR4 homodimers. The curves represent data obtained in 12 independent experiments. (C) FRETmax and FRET50 values shown were 
deduced using a nonlinear regression equation applied to a single binding site model and are representative of 8–12 independent experiments. FRETmax 
signals for CXCL12-treated and CXCL12–HMGB1-treated cells increase significantly compared with untreated cells (*, P < 0.05). Furthermore, the FRETmax 
value for CXCL12-treated cells is significantly higher (*, P < 0.05) than the FRETmax for HMGB1–CXCL12-treated cells. Error bars indicate SEM.
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DISCUSSION
The present study shows that HMGB1 promotes the recruit-
ment of inflammatory cells to injured tissues by forming a hetero-
complex with the chemokine CXCL12 that acts exclusively 
via CXCR4, the receptor for CXCL12. The CXCL12/CXCR4 
axis induces several cellular responses in vitro and in vivo, includ-
ing cell migration and recruitment of hematopoietic stem cells 
to ischemic heart (Jujo et al., 2010). We show that suboptimal 
concentrations of CXCL12, which per se do not trigger in vitro 
migration or signaling events such as ERK phosphorylation and 
intracellular Ca2+ rise, induce robust responses in the presence 
of HMGB1. This synergy might in principle be caused by the 
convergence and nonlinear response of the signaling pathways, 
to the formation of a complex between ligands, or of a complex 
between receptors. Experiments on BM cells from MyD88/, 
Tlr4/, Rage/ mice in the presence of LPS-Rs and on pre-B 
300.19 cells transfected only with human CXCR4 exclude both 
the possibilities that CXCR4 interacts with RAGE or TLR4 or 
that the downstream signaling pathways converge. That leaves 
open only the interaction of the ligands, HMGB1 and CXCL12.
We indeed show that HMGB1 and CXCL12 form a com-
plex, which we characterized by NMR and SPR experiments. 
CXCL12 can 
interact with 
the individual 
HMGB-boxes 
which abrogates the synergy between HMGB1 and CXCL12 
in vitro (Fig. 2 F). A single dose of either glycyrrhizin (200 µg) 
or anti-HMGB1 antibody (200 µg) was injected intrave-
nously 3 h before CTX-induced injury, and cellular infiltra-
tion was assessed at 6 h. Both treatments strongly inhibited 
monocyte infiltration in the injured muscle, confirming 
the relevance in vivo of the synergy between HMGB1 
and CXCL12 (Fig. 6 D).
RAGE has been indicated, so far, as the receptor re-
sponsible for HMGB1-induced migration (Orlova et al., 
2007), whereas TLR4 is responsible for HMGB1-dependent 
cytokine release (Yang et al., 2012). We investigated the 
influx of mononuclear cells after CTX injury in Rage/ 
mice (Fig. 6 E). In C57BL/6 mice, the total number of 
circulating mononuclear cells was different than in BALB/c 
mice, as was the proportion of cells recruited to damaged 
tissue (compare PBS-treated control mice in Fig. 6 [D and E]). 
The absence of RAGE in C57BL/6 mice did not pre-
vent, but actually promoted the recruitment of monocytes 
into the injured muscle, excluding the possibility that 
inflammatory cells are recruited through RAGE signaling. 
Glycyrrhizin (200 µg per mouse) also significantly inhi-
bited monocyte/macrophage recruitment in this mouse 
strain, as well as in BALB/c mice, confirming that cellular 
influx into the injured area is mediated by the HMGB1– 
CXCL12 complex.
Figure 6. Migration of WBCs in vivo depends 
on the HMGB1–CXCL12 heterocomplex. (A) WBCs 
were collected from air pouches 6 h after injection of 
PBS, 10 pmol CXCL12, 300 pmol HMGB1, or CXCL12 + 
HMGB1. Bars and error bars represent mean ± SEM 
of cell influx from at least six mice per condition  
(**, P < 0.01, ANOVA plus Dunnett’s test). (B) HMGB1–
CXCL12 heterocomplex detected by hybrid ELISA in 
the muscles injured with CTX and in the untreated 
contralateral ones. Results are expressed as fold in-
crease of the complex in CTX-treated muscle com-
pared with the untreated controls and normalized to 
the total weight of muscle. Mean ± SEM of three inde-
pendent experiments is shown (**, P < 0.01, ANOVA 
plus Bonferroni posttest). (C) Mouse cytokines were 
measured at 2 and 6 h after injury in muscles treated 
with CTX and in the untreated contralateral ones 
(control). Results are expressed as picogram/milliliter 
of cytokines detected with cytometric bead assay and 
normalized to the total weight of tissue. Mean ± SEM 
of three independent experiments is shown (**, P < 
0.01; ***, P < 0.001, ANOVA plus Bonferroni posttest). 
(D) Mononuclear CD11bhigh+ cells infiltrating the 
muscle of WT BALB/c mice were counted 6 h after 
CTX injury and normalized against circulating total 
leukocytes (WBC). Mice were treated with PBS, 
AMD3100, -HMGB1 antibody, or glycyrrhizin as 
described in Materials and methods. Mean ± SEM of 
infiltrating cells from at least three mice per condi-
tion is shown (*, P < 0.05; **, P < 0.01; ***, P < 0.005, 
ANOVA plus Dunnett’s posttest). (E) Mononuclear 
CD11bhigh+ cells infiltrating the muscles of Rage/ 
mice were counted 6 h after CTX injury and normal-
ized against circulating total leukocytes (WBC). Mice 
were treated with PBS or glycyrrhizin before injury. 
Mean ± SEM of infiltrating cells from three mice is 
shown (*, P < 0.05, ANOVA plus Dunnett’s posttest).
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IL-1 alone (Sha et al., 2008). HMGB1 also binds DNA and 
promotes its interaction with the DNA-sensing TRL9 recep-
tor (Ivanov et al., 2007).
Modulation of human leukocyte migration occurring 
via the formation of heterocomplexes between chemo-
kines has been widely studied in vitro (Paoletti et al., 2005; 
von Hundelshausen et al., 2005; Venetz et al., 2010). It was 
recently shown in vivo that monocyte recruitment into the 
atherosclerotic plaque is promoted by the formation of a het-
erodimer between the CCL5 and CXCL4 chemokines, which 
can be prevented by a peptide rationally designed to mimic 
the heterodimer interface (Koenen et al., 2009). Our in vitro 
and in vivo results show that the complex HMGB1–CXCL12 
enhances cell migration and that glycyrrhizin inhibits this 
enhancement. Of note, an NMR study showed that CXCL12 
and glycyrrhizin (Mollica et al., 2007) interact with the same 
region of HMGB1, and SPR experiments (Fig. 4) indicate that 
glycyrrhizin interferes with the formation of the HMGB1–
CXCL12 heterocomplex.
HMGB1 induces monocytes/macrophages to secrete 
TNF, among other cytokines. The HMGB1 dependence of 
the recruitment of inflammatory cells into damaged tissues 
was already shown in several animal models, most notably in 
heart ischemia/reperfusion (Andrassy et al., 2008), in perito-
nitis (Orlova et al., 2007), and in hepatitis (Sitia et al., 2007, 
2011). Indeed, we show here that an HMGB1 blocking anti-
body abolishes the recruitment of monocytes/macrophages in 
muscle tissue damaged by CTX injection and that AMD3100, 
a selective CXCR4 antagonist, interferes with recruitment 
although a higher number of inflammatory cells egress from 
the BM. We highlight that the recruitment of inflammatory 
cells to damaged tissue and the activation of the same cells 
both require HMGB1 but different receptors: CXCR4 for 
recruitment and TLR4 for activation (Yang et al., 2010, 
2012). TLR4 is triggered by oxidized HMGB1, containing 
one disulfide bond in BoxA (Yang et al., 2012), whereas in 
our work we consistently used fully reduced HMGB1, in 
which all cysteines are in the thiol form.
In our model, RAGE does not appear to be required 
for inflammatory cell recruitment. Both in vitro (Degryse 
et al., 2001) and in a mouse model heart ischemia/reperfu-
sion (Andrassy et al., 2008), the chemoattractant activity of 
HMGB1 appears to involve RAGE because it is inhibited 
by anti-RAGE antibodies, and the migration of Rage/ 
cells is severely impaired. In contrast, we propose that the 
role of RAGE in cell migration is to trigger Cxcl12 tran-
scription (Penzo et al., 2010) so that CXCL12 production 
is increased and sustained over time. Additional CXCL12 
production is unnecessary in vitro if enough CXCL12 is 
already present in the medium, or in our model of CTX-
induced muscle damage where CXCL12 is presented by 
endothelial or epithelial cells (Agace et al., 2000; Venetz 
et al., 2010).
Blocking the HMGB1–CXCL12 interaction might be 
beneficial in the early phase of tissue damage, such as in ischemic 
and trauma patients, and in chronic diseases like rheumatoid 
of HMGB1, giving similar but distinguishable NMR spectra. 
When CXCL12 is mixed in twofold excess with full-length 
HMGB1, a single set of peaks is recorded that is distinguish-
able from the spectra emerging from the interaction with 
the single HMG-boxes. We thus infer that the HMGB1–
CXCL12 complex is formed by one molecule of HMGB1 
and two molecules of CXCL12, each interacting with one 
HMG-box domain and exchanging rapidly within the hetero-
complex. The vast majority of CXCL12 residues are affected by 
the interaction with HMGB1. Notably, the N-terminal resi-
dues, which have been shown to be very flexible and respon-
sible for CXCR4 recognition and triggering (Crump et al., 
1997; Wu et al., 2010), are only affected by formation of 
the functional complex between HMGB1 and CXCL12 
molecules. Heterocomplexes forming between chemokines 
or with HMGB1 could be responsible for maintaining the 
agonist in an optimal conformation for triggering the re-
ceptor. We can also speculate that HMGB1 might bring to-
gether two molecules of CXCL12 and present them with 
the optimal spatial arrangement to a dimer of CXCR4, 
thus increasing the effective activity of CXCL12 in inducing 
cellular responses.
Our FRET data show that CXCR4 homodimers exist 
in the absence of ligands and that CXCL12 and HMGB1–
CXCL12 complexes trigger different CXCR4 homodimer 
rearrangements. In accordance with previous FRET studies 
(Percherancier et al., 2005; Levoye et al., 2009), we observed 
that addition of CXCL12 increased the maximal FRET signal, 
whereas the FRET50 value was not significantly affected. 
These data suggest that CXCL12 binding alters the confor-
mation rather than the number of preformed CXCR4 di-
mers. In contrast, HMGB1–CXCL12 addition did not modify 
FRETmax but increased FRET50 values, indicating the forma-
tion of a larger number of CXCR4 dimers. These data and 
the significant difference in FRETmax detected between cells 
activated with CXCL12 alone or with HMGB1–CXCL12 
indicated that CXCL12 and the heterocomplex differ in 
promoting rearrangements within the CXCR4 dimers. These 
effects might explain the differences observed in the activa-
tion of signaling pathways.
Our findings explain why the chemoattractant activities 
of CXCL12 and HMGB1 appear to use the same signaling 
pathways in fibroblasts, including NF-B canonical and non-
canonical pathways (Penzo et al., 2010). They also account 
for the inhibition of HMGB1-induced migration by PTX, 
which inhibits the  subunit of the Gi protein typically asso-
ciated with chemokine receptors (Murphy, 2002), and update 
our understanding of the mechanism of action of glycyrrhi-
zin, which does not only prevent the binding of HMGB1 to 
RAGE as previously proposed, but rather appears to prevent 
the formation of the HMGB1–CXC12 heterodimer.
The use of CXCR4 for HMGB1 signaling conforms to 
a general pattern whereby HMGB1 forms complexes with 
partner molecules that then act via the partner’s receptor 
(Bianchi, 2009). HMGB1 forms a heterocomplex with IL-1, 
which acts via the IL-1R receptor enhancing the activity of 
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(BioLegend), and -CCR2 (FAB5538A; R&D Systems) antibodies, and the 
population of CD11b+ was enriched using anti-PE microbeads (Miltenyi 
Biotech) and analyzed by flow cytometry per time unit (120 s) at constant 
flow. Results were normalized against the total circulating leucocytes.
The animal experimentation performed at the San Raffaele Science In-
stitute was approved by Comitato Istituzionale per la Buona Sperimetazione 
Animale della Fondazione San Raffaele del Monte Tabor on July 15, 2011. 
The animal experimentation performed at the Institute for Research in Bio-
medicine was approved by the Dipartimento della Sanitá e della Socialitá 
(Authorization N. 19/2010).
CXCL12 and HMGB1. CXCL12 was synthesized using tBoc solid-phase 
chemistry (Clark-Lewis et al., 1997). Full-length HMGB1, produced and 
stored in buffers containing DTT (Knapp et al., 2004), was provided by 
HMGBiotech S.r.l. Using the Cambrex Limulus Amoebocyte Assay QCL-
1000 (Lonza), we detected 1.1 pg LPS in 1 mg HMGB1 and 2.2 pg LPS 
after 1 mg HMGB1 was terminally digested with trypsin (therefore exclud-
ing any interference of HMGB1 with the limulus assay). The amount of 
LPS present in the assays in which HMGB1 was used is totally ineffective 
when administered alone. For NMR experiments, 15N-labeled CXCL12 or 
15N-labeled BoxB were obtained by growing Escherichia coli Rosetta cells 
(EMD) transfected with pET30 vector (EMD) containing the respective se-
quences in M9 minimal media containing 15N-H4Cl. CXCL12 was rena-
tured from inclusion bodies. BoxB and CXCL12 were purified according to 
standard techniques (Proudfoot and Borlat, 2000). CXCL12 was eluted in 
20 mM NaCl and 20 mM Na phosphate buffer, pH 6.
nSpray-ESI-MS analysis of intact proteins. Protein samples in solution 
were acidified with 10% formic acid and desalted with ZipTip C4 (Milli-
pore) according to the manufacturer’s protocol for direct nano-ESI-MS 
analysis on an LTQ-Orbitrap mass spectrometer (Thermo Fisher Scientific) 
equipped with a nanoelectrospray ion source (Proxeon Biosystems). MS 
spectra were acquired in positive ion mode in the Orbitrap from m/z 1,000–
2,500 with a resolution set to 60,000 or 100,000 at m/z 400. Peak deconvo-
lution with the Bayesian Protein Reconstruct algorithm was performed 
using Xtract from QualBrowser software (version 2.07; Thermo Fisher Sci-
entific) for molecular mass determination.
ELISA. The concentration of CXCL12 in the supernatant of 2 × 106 human 
monocytes, murine 3T3 fibroblasts, or Rage/ MEFs per milliliter stimulated 
for 2 h with HMGB1 was determined with sandwich ELISA kit (R&D Sys-
tems) according to the manufacturer’s protocol. HMGB1 bound to CXCL12 
in muscle from CTX-treated and untreated mice, obtained by muscle fragmen-
tation and tissue disaggregation in buffer containing Collagenase D (Roche), 
was determined by hybrid ELISA. In summary, the plate was coated with 
capture anti-CXCL12 antibody from ELISA kit (R&D Systems), and the 
detection of HMGB1 bound to CXCL12 in muscle was assessed with anti-
HMGB1 antibody from HMGB1 sandwich ELISA kit (IBL International). 
The hybrid ELISA did not detect HMGB1 alone or CXCL12 alone.
Cytometric bead array (CBA). IL-6, IL-10, CCL2, and TNF in muscle 
supernatant, obtained by muscle fragmentation and tissue disaggregation in 
buffer containing Collagenase D (Roche), from CTX-treated and untreated 
mice, were detected using the CBA inflammatory kit (BD) according to the 
manufacturer’s protocol.
Chemotaxis assays. Chemotaxis was assayed in 48-well Boyden micro-
chambers (Neuro Probe) as previously described (Uguccioni et al., 1995). In 
brief, CXCR4-transfected cells and freshly isolated monocytes (5 × 104) 
were diluted in RPMI 1640 supplemented with 20 mM Hepes, pH 7.4, and 
1% pasteurized plasma protein solution (5% PPL SRK; Swiss Red Cross 
Laboratory). Cells were then added to the upper wells. After 90 min of 
incubation for monocytes and 120 min for the CXCR4-transfected cells, the 
membrane was removed, washed on the upper side with PBS, fixed, and stained. 
All assays were performed in triplicate, and for each well, the migrated cells 
arthritis, where an excessive recruitment of leukocytes is sup-
ported by HMGB1 (Andersson and Harris, 2010). Notably, 
other activities of HMGB1 appear completely independent 
from the formation of the complex with CXCL12; indeed, 
HMGB1-induced TNF secretion proceeds via TLR4 (Yang 
et al., 2010), and maturation of DCs and proliferation of 
several cell types proceed via RAGE (Yang et al., 2007; un-
published data). Drugs that prevent the formation of the 
HMGB1–CXCL12 heterocomplex might be rationally de-
signed and provide a very specific tool to selectively block 
some HMGB1 effects, such as migration, without affecting 
effects induced through other receptors.
MATERIALS AND METHODS
Cells. PBMCs were isolated from buffy coats of donor blood (Central Labo-
ratory of the Swiss Red Cross, Basel, Switzerland) by Ficoll-Paque density 
centrifugation. Monocytes, CD14+, were isolated by a positive immuno-
selection procedure (CD14 MicroBeads; Miltenyi Biotec), according to the 
manufacturer’s instructions, or by Percoll gradient. Stable transfection of 
human CXCR4 in murine pre-B 300.19 was performed as described pre-
viously (Loetscher et al., 1994). Experiments performed with human 
monocytes and cells transfected with human CXCR4 were approved by 
Swiss federal authority for Biotechnology and Public Health (N.A000208/1). 
NIH/3T3 mouse fibroblasts were grown in DME supplemented with 10% 
FCS. BM cells from C57BL/6 mice (WT, Rage/, MyD88/, or Tlr4/) 
were isolated by flushing the medullary cavities of tibias and femurs with sa-
line phosphate buffer. Rage/ BM cells were incubated for 30 min in the 
presence or absence of 10 µg/ml LPS-Rs before performing chemotaxis 
assay. HEK293T cells were from the American Type Culture Collection. 
WT and mutant mouse embryonic fibroblast (MEF) matched pairs were de-
rived from same-litter embryos obtained from Rage+/ or Cxcr4+/ crosses.
Constructs. The human CXCR4 cDNA was amplified by PCR from 
pcDNA3-CXCR4 construct using the following primers and cloned into 
pECFP-N1 and pEYFP-N1 (Takara Bio Inc.): 5 HindIII (5-ATAAGCT-
TATGGAGGGGATCAGTATATACATTC-3) and 3 AgeI (5-GACCGG-
TGGATCCCGTAAGCTGGAGTGAAAACTTGAAG-3). mGluR1 
cloned into pEYFP-N1 vector (mGluR1-YFP) was provided by R. Franco 
(Universidad Autònoma de Barcelona, Barcelona, Spain).
Mice and treatments. C57BL/6 and BALB/c mice were purchased from 
Harlan and the Jackson Laboratory, respectively, and C57BL/6 MyD88/ 
mice (Adachi et al., 1998) were provided by S. Akira (Osaka University, 
Suita, Osaka, Japan). C57BL/6 Rage/ mice (Liliensiek et al., 2004) were 
provided by A. Bierhaus (University of Heidelberg, Heidelberg, Germany). 
C57BL/6 Tlr4/ mice were provided by M. Manz (University of Zurich, 
Zurich, Switzerland). Cxcr4+/ mice (Zou et al., 1998) were provided by 
D. Littman (New York University School of Medicine, New York, NY). 
Sterile injury was induced by injection of 15 µM CTX in the TA muscle. 
Air pouches were established in 8-wk-old male C57BL/6 mice by injecting 
subcutaneously 5 ml and 3 ml of air at day 0 and day 3, respectively. At day 6, 
mice were injected with 200 µl PBS, 10 pmol CXCL12, 300 pmol 
HMGB1, or 10 pmol CXCL12 + 300 pmol HMGB1 in the air pouch. After 
6 h, cells were collected from the air pouch and stained with -Ly6C (BD) 
and -CD11b (BioLegend) antibodies. For AMD3100 pretreatment, mice 
were implanted with mini-osmotic pumps (DURECT Corporation) that 
infused 1.3 mg AMD3100 or an equivalent volume of saline over a period 
of 3 d before CTX injury (Jujo et al., 2010). For glycyrrhizin or -HMGB1 
antibody pretreatment, mice were injected intravenously with 200 µg glycyr-
rhizin (Minophagen Pharmaceutical Co.) or -HMGB1 monoclonal anti-
body DPH1.1 3 h before CTX-induced injury. After 6 h, infiltrating cells 
were isolated from muscles at 37°C in a buffer containing Collagenase P and 
Collagenase D (Roche). Cells were stained with -Ly6C (BD), -CD11b 
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sensor channels, showing increased binding to HMGB1 at increasing con-
centration. In a second experiment, glycyrrhizin was flowed over the surface 
at concentrations of 0, 500, or 5,000 nM, followed by the addition of 500 nM 
CXCL12. CXCL12 binding to HMGB1 was detected in all cases, but the 
signal intensity decreased at increasing concentrations of glycyrrhizin. All 
experiments were conducted at pH 6.0 in 20 mM Na phosphate buffer 
and 20 mM NaCl. Several reference channels were used, either flowing 
CXCL12 and glycyrrhizin over a sensor surface in the absence of HMGB1 
or flowing buffer without CXCL12 or glycyrrhizin over a surface with 
immobilized HMGB1.
FRET experiments. FRET saturation curves were performed as described 
previously (Martínez Muñoz et al., 2009). Gain settings were identical for all 
experiments to maintain a constant relative contribution of fluorescent pro-
teins to the detection channels for spectral imaging and linear unmixing 
(Zimmermann et al., 2002). The contribution of CFP and YFP alone was 
measured in each detection channel (spectral signature) and normalized to 
the sum of the signal obtained for both channels. For quantitation, the spec-
tral signature was taken into consideration for linear unmixing to separate 
the two emission spectra. To determine the fluorescence emitted by each 
fluorescent protein, we applied the following general formulas: CFP = S/(1 + 
1/R) and YFP = S/(1 + R), where S = ChCFP + ChYFP, R = ((YFP530Q)  
YFP486)/(CFP486  (CFP530Q)), and Q = ChCFP/ChYFP. ChCFP and 
ChYFP represent the signal in the 486- and 530-nm detection channels (Ch); 
CFP486, CFP530, YFP530, and YFP486 represent the normalized contributions 
of CFP and YFP to channels 486–530, as determined from spectral signa-
tures of the fluorescent proteins.
Statistics. Statistical analysis was performed using the two-tailed Student’s 
t test (unpaired) for means in the CXCL12 measurements by ELISA. Migra-
tion assays with CXCL12 and HMGB1 and CBA measurements of cyto-
kines were analyzed by analysis of variance (ANOVA) plus Bonferroni 
posttest. ANOVA followed by Dunnett’s multiple comparison tests was used 
for the in vivo experiments and migration of 3T3 mouse fibroblasts. To de-
termine FRET50 and FRETmax, values were extrapolated from data analysis 
using a nonlinear regression equation applied to a single binding site model 
with a 95% confidence interval (Prism 5.0; GraphPad Software).
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were counted at 1,000-fold magnification in randomly selected fields. The 
following reagents were used to inhibit cell migration: PTX (EMD), anti-
CXCR4 (Abcam), anti-CXCL12 (K15C; provided by F. Arenzana-Seisdedos, 
Institut Pasteur, Paris, France), and AMD3100 (Sigma-Aldrich).
Intracellular Ca2+ rise. Pre-B 300.19–CXCR4+ cells (0.3 × 106) in 100 µl 
were loaded with Fura-2-AM (final concentration 50 nM) on poly-lysine–
coated slides. Loaded cells were washed with buffer containing 155 mM 
NaCl, 4.5 mM KCl, 5 mM Hepes, 1 mM MgCl2, 2 mM CaCl2, and 10 mM 
glucose, and imaging was recorded with a 40× oil-immersion objective on 
an inverted microscope (Axiovert 200; Carl Zeiss) with excitation at 340 nm 
and 380 nm using the Polychrom V illumination system from TILL Photon-
ics GmbH. Chemokines were injected after 60 s of recording, and recording 
was continued up to 3 min. The 340/380 ratio provides a relative measure 
of cytoplasmic-free Ca2+ concentration.
ERK phosphorylation. Freshly isolated monocytes (106 cells/time point) 
were incubated in RPMI/Hepes for 10 min at 37°C and stimulated with 
CXCL12 ± HMGB1. The reaction was stopped by the addition of 10% 
trichloroacetic acid. Whole cell lysates were separated on 11% SDS-PAGE 
and transferred to polyvinylidene difluoride membranes. Activated ERK 
was detected with an anti–diphospho-ERK antibody (1:10,000; Sigma-
Aldrich). Enhanced chemiluminescence was used for detection of horseradish 
peroxidase–conjugated secondary antibody (Bio-Rad Laboratories, Hercules, 
CA). Equal loading was confirmed by reprobing with an anti-GAPDH anti-
body (AbD Serotec). Densitometric analysis of the bands obtained by 
Western blotting was performed with AIDA software (Aida Image analyzer 
version 3.28).
Pull-down of CXCR4. Pre-B 300.19–CXCR4+ cells were incubated 
with biotinylated or nonbiotinylated CXCL12 or HMGB1 at 500 nM for 
10 min on ice. Cells were lysed in 30 mM Hepes, 100 mM KCl, 20 mM NaCl, 
2 mM MgCl2, 5% glycerol, 5 µM GDP, 2% Heptanetriol, 0.4% lauryl malto-
side, 0.08% cholesteryl hemisuccinate, 1 µM microcystin, 1 mM NaVO4, 
and Complete protease inhibitors (Roche). Receptor–ligand complexes 
were pulled down using streptavidin-Sepharose (SA; GE Healthcare) and 
eluted using sample buffer containing 50 mM Tris-HCl, pH 6.8, 2% glyc-
erol, 100 mM Na dodecyl-sulfate, and bromophenol blue. CXCR4 was 
analyzed by Western blotting using anti-CXCR4 (SZ1567; custom pre-
pared; Eurogentec) and horseradish peroxidase–conjugated goat anti–rabbit 
antibody (Santa Cruz Biotechnology, Inc.). Enhanced chemiluminescence 
was used for detection according to the manufacturer’s instructions (Thermo 
Fisher Scientific).
NMR experiments. 15N-HSQC experiments were performed on a Bruker 
700-MHz spectrometer with CryoProbe. Acquisition time varied between 
30 min (free CXCL12 or BoxB) and 16 h (complexes). An HSQC spectrum 
was recorded on the free, labeled component; a second HSQC was recorded 
after addition of the unlabeled partner (1:1 ration for the CXCL12–BoxB or 
–BoxA complexes; 2:1 for CXCL12–HMGB1). Backbone assignments were 
obtained by comparison to previously published data (Biological Magnetic 
Resonance Bank accession numbers 15148, 15149, and 16145).
Chemical shift mapping. Residues whose NMR signal changes position 
upon complex formation were identified by visual comparison of free and 
bound spectra of CXCL12 or BoxB in complex with partners. For quantita-
tive analysis, the amount of chemical shift change upon complex formation 
was calculated for each residue according to the formula  2 2 ,0.2N H' x '  
where N and H are the chemical shift difference between free and bound 
spectrum in the nitrogen and proton dimension.
SPR. SPR experiments were performed on a Proteon-XPR36 instrument 
(Bio-Rad Laboratories). HMGB1 was immobilized on a GLM sensor surface 
through amine coupling according to standard protocols. In a first experi-
ment, CXCL12 was added at concentrations of 250 and 500 nM in different 
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